Earlier in May 2026, NeoGenomics, Inc. announced it would present eight scientific abstracts at the 2026 ASCO Annual Meeting in Chicago, highlighting advances in hematologic malignancy testing, ...

A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% ...

Biognosys’ leading discovery proteomics services to add depth to NeoGenomics’ multiomics solutions for biopharma clinical trials and research The two companies will present scientific posters at the ...

NeoGenomics ( (NEO) ) has issued an update. On May 21, 2026, NeoGenomics, Inc. held its annual meeting of stockholders, where investors approved an amendment to the 2023 Equity Incentive Plan to add 5 ...

NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. I ...

CEO Anthony Zook highlighted record clinical volumes and revenues for the third quarter of 2025, emphasizing the company’s progress in next-generation sequencing (NGS) and minimal residual disease ...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first ...

Clinical Trial Matching Collaboration Will Enhance Identification of Patients with Any Solid Tumor Harboring an NRG1 Gene Fusion Identified Using NeoGenomics' Advanced Gene Fusion Panels FORT MYERS, ...

NeoGenomics (NEO), a Fort Myers-based cancer testing and research lab, surprised Wall Street Monday with higher-than-expected third-quarter revenue and break-even earnings per share. The company ...